# EDGAR Filing Document

**Accession Number:** 0001840877
**File Stem:** 0001213900-25-068760
**Filing Date:** 2025-7
**Character Count:** 11945
**Document Hash:** 1f3acdc77094c05e053ee40a38743899
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-068760.hdr.sgml**: 20250729

**ACCESSION NUMBER**: 0001213900-25-068760

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250728

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250729

**DATE AS OF CHANGE**: 20250729

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Envoy Medical, Inc.
- **CENTRAL INDEX KEY:** 0001840877
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 861369123
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40133
- **FILM NUMBER:** 251162514

**BUSINESS ADDRESS:**
- **STREET 1:** 4875 WHITE BEAR PARKWAY
- **CITY:** WHITE BEAR LAKE
- **STATE:** MN
- **ZIP:** 55110
- **BUSINESS PHONE:** 651-361-8000

**MAIL ADDRESS:**
- **STREET 1:** 4875 WHITE BEAR PARKWAY
- **CITY:** WHITE BEAR LAKE
- **STATE:** MN
- **ZIP:** 55110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anzu Special Acquisition Corp I
- **DATE OF NAME CHANGE:** 20210115

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 28, 2025**

**ENVOY MEDICAL, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40133** | **86-1369123** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission File Number)** | **(IRS Employer<br> Identification No.)** |

---

---

| | |
|:---|:---|
| **4875 White Bear Parkway<br> White Bear Lake, MN** | **55110** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (877) 900-3277**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Class A Common Stock, par value $0.0001 per share** | **COCH** | **The Nasdaq Stock Market LLC** |
| **Redeemable Warrants, each whole Warrant<br> exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share** | **COCHW** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐¨

**Item 1.01 Entry into a Material Definitive Agreement.**

Envoy Medical, Inc. (the "<u>Company</u>") has previously issued Stock Purchase Warrants (the "<u>Shortfall Warrants</u>") to Meteora Special Opportunity Fund I, LP ("<u>MSOF</u>"), Meteora Capital Partners, LP ("<u>MCP</u>"), Meteora Select Trading Opportunities Master, LP ("<u>MSTO</u>") and Meteora Strategic Capital, LLC ("<u>MSC</u>" and, collectively with MSOF, MCP and MSTO, the "<u>Meteora Parties</u>") pursuant to the terms of the Equity Prepaid Forward Transaction, dated as of April 17, 2023, by and among the Company, Envoy Medical Corporation, and the Meteora Parties.

On July 28, 2025, the Company and the Meteora FPA Parties entered into an Amendment No. 3 to Common Stock Purchase Warrant to amend the 3,209,511 Shortfall Warrants that remain outstanding to change the exercise price (the "<u>Warrant Amendment</u>"). Pursuant to the Warrant Amendment, the exercise price of the Shortfall Warrants is determined based on a volume weighted average price (VWAP) formula, measured weekly, and subject to a minimum price of $1.50 per share.

The issuance and resale of the shares of the Company's Class A Common Stock issuable upon exercise of the Warrants and the resale of the Shortfall Warrants were registered pursuant to the Company's Registration Statement on Form S-1 (File No. 333-276590), which was declared effective by the U.S. Securities and Exchange Commission on May 2, 2024.

The foregoing description of the Warrant Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Warrant Amendment, which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit** |
| 10.1 | [Amendment to Forward Stock Purchase Agreement, between the Meteora FPA Parties and the Company, dated July 28, 2025.](ea025064901ex10-1_envoy.htm) |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: July 29, 2025 | **ENVOY MEDICAL, INC.** | **ENVOY MEDICAL, INC.** |
|  | By: | /s/ Brent Lucas |
|  |  | Brent Lucas |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**AMENDMENT NO. 3 TO<br> COMMON STOCK PURCHASE WARRANT**

This AMENDMENT NO. 3 TO COMMON STOCK PURCHASE WARRANT (this "<u>Amendment</u>") is entered into as of July 29, 2025, by and between Envoy Medical, Inc., a Delaware corporation (the "<u>Company</u>"), and Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP and Meteora Strategic Capital, LLC (collectively, the "<u>Holder</u>"). Capitalized terms used herein and not otherwise defined are defined in the Original Warrant (as defined below).

WHEREAS, the Holder is the holder of a Common Stock Purchase Warrant, issued as of November 27, 2023, to purchase up to 3,874,394 shares of Common Stock (as amended by the Amendment No. 1 to Common Stock Purchase Warrant, dated as of June 24, 2024 and Amendment No. 2 to Common Stock Purchase Warrant, dated as of December 19, 2024, the "<u>Original Warrant</u>");

WHEREAS, the Original Warrant was issued pursuant to the terms of that certain Confirmation of an OTC Equity Prepaid Forward Transaction, dated as of April 17, 2023, by and among the Company, the Holder, and the Company's wholly-owned subsidiary Envoy Medical Corporation (as amended by the letter agreements, dated as of May 25, 2023 and September 28, 2023, and as further amended by the Forward Purchase Agreement Confirmation Amendment, dated as of July 29, 2024, the "<u>Forward Purchase Agreement</u>");

WHEREAS, pursuant to Section 5(m) of the Original Warrant, the Original Warrant may be modified or amended or the provisions thereof waived with the written consent of the Company and the Holder; and

WHEREAS, the Company and the Holder desire to amend the Original Warrant as set forth in this Amendment.

NOW, THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and the Holder hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Amendment to Exercise Price</u>. The Original Warrant is hereby amended by deleting and replacing clause 2(b) "<u>Exercise Price</u>" and replacing it with the following:

"The exercise price per share of Common Stock under this Warrant shall be set at the beginning of each week to equal the greater of (i) the prior week's volume weighed average price of COCH stock as reported by Bloomberg and (ii) $1.50, subject to adjustment hereunder (the "<u>Exercise Price</u>")."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>No Further Amendment</u>. Except as amended by this Amendment, the Original Warrant remains unaltered and shall remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Acknowledgements and Other Agreements</u>. The parties hereto acknowledge and agree that, notwithstanding anything to the contrary set forth in the Forward Purchase Agreement, no amendment to the Forward Purchase Agreement is necessary to effect the terms of this Amendment, and the Termination Date as set forth in this Amendment shall supersede the expiration date of the Shortfall Warrants as provided in the Forward Purchase Agreement. The parties hereto further agree that the adjustment to the exercise price set forth in the Original Warrant provided for by the Forward Purchase Agreement Confirmation Amendment, dated as of July 29, 2024, shall remain in effect without change as a result of this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Amendment shall be determined in accordance with the provisions of the Forward Purchase Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Counterparts</u>. This Amendment may be executed in any number of counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. Signatures delivered by facsimile, electronic mail (including as a PDF file) or other transmission method shall be deemed to be original signatures, shall be valid and binding, and, upon delivery, shall constitute due execution of this Amendment.

**(Signature page follows)**

IN WITNESS WHEREOF, each of the Company and the Holder has caused this Amendment to be executed by its officer thereunto duly authorized as of the date first above indicated.

---

| | |
|:---|:---|
| **ENVOY MEDICAL, INC.** | **ENVOY MEDICAL, INC.** |
| By: | /s/ Brent Lucas |
| Name: | Brent Lucas |
| Title: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| **METEORA SPECIAL OPPORTUNITY FUND I, LP**<br> **METEORA CAPITAL PARTNERS, LP**<br> **METEORA SELECT TRADING OPPORTUNITIES MASTER, LP**<br> **METEORA STRATEGIC CAPITAL, LLC** | **METEORA SPECIAL OPPORTUNITY FUND I, LP**<br> **METEORA CAPITAL PARTNERS, LP**<br> **METEORA SELECT TRADING OPPORTUNITIES MASTER, LP**<br> **METEORA STRATEGIC CAPITAL, LLC** |
| By: | /s/ Vikas Mittal |
| Name: | Vikas Mittal |
| Title: | CIO/Managing Member |

---

Acknowledged and Agreed,

---

| | |
|:---|:---|
| **ENVOY MEDICAL CORPORATION** | **ENVOY MEDICAL CORPORATION** |
| By: | /s/ Brent Lucas |
| Name: | Brent Lucas |
| Title: | Chief Executive Officer |

---

*[Signature Page to Amendment No. 3 to Common Stock Purchase Warrant]*